[2] 0tt I，Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment[J]. Anticancer Agents Med Chem，2007，7(1) : 95 － 110.
[2] Kataja V，Castiglione M，ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis，treatment and follow-up[J]. Ann Oncol，2008，19(2) : 9 － 11.
[3] Stokes ME，Thompson D，Montoya EL，et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEERmedicare data[J]. Value Health，2008，11(2) : 213 － 220.
[4] 马磊，陈文晟，彭美芳，等. GEM 联合5-Fu 和CF 双周方案二线治疗晚期乳腺癌[J]. 临床肿瘤学杂志，2006，11 (1 ) : 32 － 34.
[5] McDonald AC，Vasey PA，Adams L，et al. A phase Ⅰ and pharmacokinetic study of LY231514，the multitargeted antifolate[J]. Clin Cancer Res，1998，4(3) : 605 － 610.
[6] Ferrero JM，Chamorey E，Magn N，et al. The raltitrexedvinorelbine combination: a phase Ⅰ pharmacokinetic and pharmaeodynamic trial in advanced breast cancer[J]. Cancer Chemother Pharmacol，2002，50(6) : 459 － 464.
[7] 胡国志，武英蕾，杨宏，等. 雷替曲塞联合长春瑞滨治疗蒽环及紫杉类耐药的晚期三阴乳腺癌的疗效和安全性评估[J]. 现代中西医结合杂志，2012，21(33) : 3678 － 3680.
[8] Maughan T，James R，Kerr D，et al. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimen in the palliative chemotherapy of advanced colorectal cancer (CRC) : final results of MRC CRO6[J]. Ann Oncol，2000，11(Suppl 4) : a1850.
[9] Wilson KS，Malfair Taylor SC. Raltitrexed: optimism and reality[J]. Expert Opin Drug Metab Toxicol，2009，5 (11 ) : 1447 －1454.
[10] Jarmula A. Antifolate inhibitors of thymidylate synthase as anticancer drugs[J]. Mini Rev Med Chem，2010，10 (13 ) :1211 － 1222.
[11] 王佳蕾，李进，秦叔逵，等. 雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J]. 临床肿瘤学杂志，2012，17(1) :6 － 11.